You searched for
Tag:
Products
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
07/03/2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17/01/2023
Chiesi Group endorses the Manifesto Against Gender-Based Violence
28/11/2022
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
21/11/2022
Chiesi announces the departure of Ugo Di Francesco as CEO of the Group
31/08/2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27/07/2022
Chiesi tracks actions taken for a healthier, more sustainable future
14/07/2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02/05/2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16/12/2021
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
14/12/2021
Chiesi Group Headquarters takes centre stage in the monograph “SPAZIO LAVORO ARCHITETTURA” (SPACE WORK ARCHITECTURE) Electaarchitettura editions
13/12/2021
Chiesi Research Centre: 10 years’ scientific innovation serving the community
18/10/2021
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07/09/2021